Melanoma Research Alliance Statement on FDA Approval of Relatlimab + Nivolumab for Treatment of Advanced Melanoma
WASHINGTON--(BUSINESS WIRE)--The Melanoma Research Alliance (MRA) released the following statements from MRA’s Chief Science Officer Marc Hurlbert, PhD and President & CEO Michael Kaplan on the Food & Drug Administration approval of relatlimab plus nivolumab: MRA Chief Science Officer Marc Hurlbert, PhD: “It is exciting to see a new, first in class, immunotherapy against the checkpoint LAG-3, a veritable roadblock suppressing the immune systems from attacking cancers, be approved for th